KRM Ayurveda September revenue rises 47%, profit nearly doubles

KRM Ayurveda Limited reported revenue from operations of Rs 34.7144 crore for the quarter ended September 30, 2026, 46.5% above the prior-year quarter, while profit for the period rose 97.3% to Rs 8.2281 crore. The Board approved the unaudited standalone results on November 13, 2026.

How did KRM Ayurveda perform in the September quarter?

KRM Ayurveda recorded total income of Rs 35.3573 crore in the September 2026 quarter, compared with Rs 23.838 crore in the quarter ended September 30, 2025. Revenue from operations contributed Rs 34.7144 crore, while other income was Rs 64.29 lakh, up from Rs 14.73 lakh a year earlier.

KRM Ayurveda’s profit before tax rose to Rs 10.8728 crore from Rs 5.5818 crore in the year-earlier quarter. Current tax expense increased to Rs 2.7423 crore from Rs 1.4035 crore, while deferred tax was a credit of Rs 9.75 lakh, resulting in profit for the period of Rs 8.2281 crore against Rs 4.1698 crore.

KRM Ayurveda reported basic and diluted earnings per equity share of Rs 3.87 for the quarter ended September 30, 2026, compared with Rs 2.69 for September 2025. The results statement identifies both per-share figures as not annualised and was prepared under Accounting Standard 25, Interim Financial Reporting.

What changed from the June 2026 quarter?

KRM Ayurveda’s revenue from operations increased 7.4% sequentially, from Rs 32.3226 crore in the quarter ended June 30, 2026 to Rs 34.7144 crore in the September quarter. Total income rose from Rs 32.8655 crore to Rs 35.3573 crore as other income increased by Rs 10 lakh to Rs 64.29 lakh.

KRM Ayurveda’s profit for the period fell 9.4% sequentially, from Rs 9.0845 crore in June 2026 to Rs 8.2281 crore in September 2026. Profit before tax declined from Rs 12.2349 crore to Rs 10.8728 crore because total expenses rose by Rs 3.8539 crore, more than the Rs 2.4918 crore increase in total income.

KRM Ayurveda’s employee benefits expense increased by Rs 1.5213 crore sequentially and other expenses rose by Rs 1.2008 crore. Cost of materials consumed increased from Rs 2.52 crore in June to Rs 3.5143 crore in September, while depreciation and amortisation rose from Rs 26.37 lakh to Rs 38.17 lakh.

What do KRM Ayurveda’s half-year results show?

KRM Ayurveda generated revenue from operations of Rs 67.037 crore for the half year ended September 30, 2026, up 38.6% from Rs 48.3571 crore in the corresponding 2025 half year. Total income increased to Rs 68.2228 crore from Rs 48.6543 crore, including other income of Rs 1.1858 crore versus Rs 29.72 lakh.

KRM Ayurveda’s half-year profit for the period more than doubled to Rs 17.3126 crore from Rs 8.2227 crore. Profit before tax rose to Rs 23.1077 crore from Rs 11.0032 crore, while total expenses increased to Rs 45.1151 crore from Rs 37.6511 crore over the same periods.

KRM Ayurveda’s cost mix changed in the half-year comparison. Cost of materials consumed declined to Rs 6.0344 crore from Rs 8.4578 crore, but employee benefits expense rose to Rs 13.4295 crore from Rs 10.0425 crore and other expenses increased to Rs 24.8622 crore from Rs 16.9048 crore. Finance costs declined to Rs 14.37 lakh from Rs 1.711 crore.

What do the balance sheet and cash flows show?

KRM Ayurveda reported total assets of Rs 147.2165 crore at September 30, 2026, compared with Rs 122.276 crore at March 31, 2026. Trade receivables increased to Rs 39.0856 crore from Rs 22.7272 crore, while inventories rose to Rs 16.6006 crore from Rs 9.0285 crore during the six months.

KRM Ayurveda’s cash and cash equivalents declined to Rs 6.5794 crore at September 30 from Rs 9.4688 crore at the start of the financial year. Net cash used in operating activities was Rs 4.5317 crore for the half year, compared with net cash from operating activities of Rs 2.2842 crore in the corresponding 2025 period.

KRM Ayurveda’s cash-flow statement recorded Rs 16.3584 crore of cash use from higher trade receivables and Rs 7.5721 crore from higher inventories. Cash generated from operations was negative Rs 53.93 lakh despite half-year profit before tax of Rs 23.1077 crore, and direct taxes paid were Rs 3.9923 crore. Proceeds from short-term borrowings were Rs 3.2789 crore.

What are the key reporting and audit disclosures?

KRM Ayurveda operates in one business segment, trading of Ayurvedic medicines and providing Ayurvedic therapies, so the filing gives no separate product, therapy or geographic revenue split. Its equity shares were listed on the NSE SME Emerge Platform on January 29, 2026, according to the notes to the results.

KRM Ayurveda’s statutory auditor, Shiv & Associates, conducted a limited review rather than an audit of the September 2026 standalone results. The auditor said the September 30, 2025 comparative quarter was not subject to limited review under the previous Indian Generally Accepted Accounting Principles basis, and its conclusion does not cover those figures.

KRM Ayurveda’s results table is labelled unaudited standalone, while a note states that an accompanying statement includes results of wholly owned subsidiary Karma Nutravedics Private Limited from July 3, 2026. The filing does not provide a separate consolidated financial-results table or comparative prior-year consolidated numbers, so the reported comparisons above use the standalone table.

Conclusion

KRM Ayurveda delivered year-on-year growth in the September 2026 quarter, with revenue from operations increasing by Rs 11.0237 crore and profit for the period rising by Rs 4.0583 crore. The sequential comparison was different: revenue increased from the June quarter, but profit declined by Rs 85.64 lakh as employee, material and other expenses rose.

The next reported results can show whether KRM Ayurveda converts its higher receivables and inventories into operating cash, after receivables rose by Rs 16.3584 crore and inventories by Rs 7.5721 crore from March 31, 2026. Investors can also watch for further disclosure on Karma Nutravedics Private Limited and separately presented consolidated figures following its July 3, 2026 acquisition as a wholly owned subsidiary.